Message from the President

We are determined to contribute to human health and medical advancement through our ongoing development of innovative diagnostic technologies.

MBL began its history as the first Japanese company specializing in the production and supply of antibodies and celebrated its 50th anniversary in August 2019. In the 1970s, for the first time in Japan, we began to develop autoimmune disease reagents and succeeded in launching a series of autoantibody reagents. Currently, these reagent products are our main-stream business. In the 1980s, we expanded business into the field of laboratory research reagents and launched many original products such as antiserum and monoclonal antibodies, IL-18 products, and MHC tetramers. Starting in the 2000s, we began to promote sales of molecular diagnostic reagents, and this business has grown to become our second largest sector. Then we have begun contract R&D services for developing companion diagnostics from last year. We expanded business operations into China in 2005. Since then, revenue has been steadily increasing not only for laboratory research reagents but also for raw materials and intermediates of diagnostic reagents. China is now one of the most important market for the company. We are committed to providing a range of cutting-edge products and services that will benefit society.

In FY 2020, we adopted our new corporate philosophy and set forth our long-term vision for future. Our long-term vision is to be “A top global niche company that contributes to the health of people, and advances the progress of medical science and health care. This will be achieved by maximizing corporate value through proactive input of innovative diagnostic technologies and the products created from them. By doing this, we will expand our overseas business activities and create new business.” These initiatives will be guided by the corporate philosophy of “contributing to the health of people and the progress of medicine with innovative diagnostic technologies.” In FY 2020, we began to execute the new medium-term management plan, “Next Stage 2020–2024,” as part of the process to achieve our long-term vision. We will continue to take on the challenge of value creation as a top global niche company with the highest level of technology, quality, and operational excellence in the cutting-edge field of diagnostics.

In recent years, the sophistication and individualization of medical care have been making rapid progress. For example, in the field of pharmaceuticals on the market, the launched products have changed from past blockbusters to personalized medicines (highly effective drugs) which are discovered through molecular pathways of certain diseases. When using these medicines in the clinical setting, it is possible to increase treatment effect and reduce adverse reactions by evaluating efficacy and safety parameters using companion diagnostics or biomarkers. Such cutting-edge diagnostic reagents have come to play an important role by helping the physician to make a decision on the best treatment approach, in addition to the conventional decision-making process that includes patient interview, physical examination, and laboratory tests.

Medical science and medicines are becoming highly sophisticated, while at the same time the need for accurate and rapid diagnostic reagents has sharply increased because of the new coronavirus pandemics that has been sweeping the globe since the beginning of this year. It is concerned and worried that the prevalence of new or recurring virus infections emerging in the future may again lead to the substantial curtailment of both social and business activities and cause a major global economic recession. Clearly, as a key infection-control measure, there is a strong need for virus test kits capable of making a rapid diagnosis.

MBL is committed to being a leading manufacturer and supplier of diagnostic reagents that facilitate further advances in personalized medicine and individualization of medical care and responding to strong medico-social needs such as quick and accurate infectious disease diagnosis. It is my sincere hope that you will grant us your continued support and guidance.

April 1st, 2021

President and CEO
Kimimasa Yamada